Daratumumab monotherapy for relapsed/refractory multiple myeloma, focused on clinical trial‐unfit …,

… including 64 trial‐unfit patients whose features failed to satisfy inclusion criteria in two prior clinical trials (GEN501 and SIRIUS), researchers focused …, … including 64 trial‐unfit patients whose features failed to satisfy inclusion criteria in two prior clinical trials (GEN501 and SIRIUS), researchers focused …, Read More